# US 2021/0277049 A1 · Cocrystal of progesterone and preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277049 A1
- Document ID: US20210277049A1
- Status: Published application
- Kind: A1
- Application number: 17/191,769
- Filed: 2021-03-04
- Published: 2021-09-09
- Earliest claimed: 2020-03-09
- Assignees: National Institutes for Food and Drug Control
- Applicants: National Institutes for Food and Drug Control
- Inventors: Lan He; Jing Xiong; Xiangxiang Wu; Xin Zhu; Zhonglin Lu; Yan Shi; Na Zhang; Yang Liu
- Web page: https://patentgrep.com/patent/US20210277049A1

## CPC

- C07J 5/0015: {not substituted in position 16}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 15/12: for climacteric disorders
- C07J 1/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to a cocrystal of progesterone, which is formed by the active ingredient progesterone and a cocrystal former which is selected from isophthalic acid, 4-formylbenzeneboronic acid and 3-nitrophthalic acid. The present invention also relates to the method for preparing the cocrystal of progesterone and use thereof for increasing the thickness of endometrium, improving progesterone's solubility or increasing progesterone's permeation rate.

## Claims

### Claim 1

A cocrystal of progesterone, characterized in that the cocrystal of progesterone is formed by the active ingredient progesterone and a cocrystal former which is selected from the group consisting of isophthalic acid, 4-formylbenzeneboronic acid and 3-nitrophthalic acid.

### Claim 2 (depends on 1)

The cocrystal of progesterone according to claim 1, characterized in that progesterone and the cocrystal former are present in a molar ratio of 1:3 to 3:1.

### Claim 3 (depends on 1)

The cocrystal of progesterone according to claim 1, characterized in that progesterone is connected to the cocrystal former via hydrogen bonds.

### Claim 4 (depends on 1)

The cocrystal of progesterone according to claim 1, characterized in that
(1) where the cocrystal former is isophthalic acid, a progesterone-isophthalic acid cocrystal is obtained, wherein the progesterone-isophthalic acid cocrystal belongs to a triclinic system with a space group of P1 and unit cell parameters of a=21.889(6) Å, b=7.4735(17) Å, c=16.423(4) Å, α=γ=90°, β=125.052(14), V=2199.3(9) Å3 and Z=4; ρcalcg=1.228 cm3; μ=0.083 mm−1; F(000)=880; radiation of Mo-Kα; 2θ range of 1.51° to 27.51°; index ranges of −28≤h≤28, −9≤k≤9 and −20≤l≤21; reflections collected=14151; unique reflections, Rint=4693, 0.2434; unique reflections data/restraints/parameters=4693/5/277; goodness-of-fit (GOF)=0.912; R1[I>2(I)]=0.0677; wR2(a11)=0.2780; and largest difference peak/hole=0.725/−0.801 e Å−3; and powder X-ray diffraction characteristic peaks of the progesterone-isophthalic acid cocrystal, expressed as 20 angles, appear at 6.56°, 10.96°, 13.14°, 16.17°, 19.76°, 20.32°, 21.04°, 22.20°, 24.17°, 26.45°, 28.05° and 28.55°;
(2) where the cocrystal former is 4-formylbenzeneboronic acid, a progesterone-4-formylbenzeneboronic acid cocrystal was obtained, wherein the progesterone-4-formylbenzeneboronic acid cocrystal belongs to an orthorhombic system with a space group of P212121, and unit cell parameters of a=9.2744(17)Å, b=14.001(3)Å, c=19.632(4)Å, α=β=γ=90°, V=2549.2(8)Å3 and Z=4; ρcalcg=1.215 cm3; μ=0.081 mm−1; F(000)=1000; radiation of Mo-Kα; 2θ range of 3.35° to 27.50°; index ranges of −12≤h≤10, −18≤k≤18 and −25≤l≤21; reflections collected=17964; unique reflections, Rint=5828, 0.0488; unique reflections data/restraints/parameters=5828/0/311; goodness-of-fit (GOF)=0.918; R1[I>2(I)]=0.0476; wR2(a11)=0.1281; and largest difference peak/hole=0.144/−0.147 e Å−3; and powder X-ray diffraction characteristic peaks of the progesterone-4-formylbenzeneboronic acid cocrystal, expressed as 20 angles, appear at 9.04°, 10.55°, 12.64°, 13.44°, 15.53°, 16.48°, 16.99°, 18.22°, 19.11°, 19.66°, 20.70°, 21.18°, 22.12°, 23.48°, 24.68°, 26.63° and 27.85°; and
(3) where the cocrystal former is 3-nitrophthalic acid, a progesterone-3-nitrophthalic acid cocrystal is obtained, wherein the progesterone-3-nitrophthalic acid cocrystal belongs to an orthorhombic system with a space group of P212121, and unit cell parameters of a=7.7804(8)Å, b=15.6533(15)Å, c=22.414(2)Å, α=β=γ=90°, V=2729.8(5)Å3 and Z=4; ρcalcg=1.323 cm3; ρ=0.098 mm−1; F(000)=1160; radiation of Mo-Kα; 2θ range of 1.59° to 25.44°; index ranges of −8≤h≤9, −18≤k≤18 and −27≤l≤23; reflections collected=14423; unique reflections, Rint=5036, 0.0304; unique reflections data/restraints/parameters=5036/3/366; goodness-of-fit (GOF)=1.004; R1[I>2(I)]=0.0409; wR2(a11)=0.1101; and largest difference peak/hole=0.226/−0.223 e Å−3; and powder X-ray diffraction characteristic peaks of the progesterone-3-nitrophthalic acid cocrystal, expressed as 20 angles, appear at 9.08°, 13.01°, 13.39°, 13.78°, 15.88°, 16.55°, 18.78°, 19.29°, 20.87°, 23.34°, 26.27°, 27.33° and 29.79°.

### Claim 5 (depends on 1)

A method for preparing the cocrystal of progesterone according to claim 1, characterized in that the method comprises the following steps: mixing progesterone and the cocrystal former in proportion, adding a solvent and stirring at 0 to 80° C. for 30 to 360 min until a completely clear solution is obtained, then allowing the solution to stand at room temperature for 3 to 15 days to volatilize the solvent and precipitate crystals, and obtaining a cocrystal of progesterone after filtrating and drying.

### Claim 6 (depends on 5)

The method according to claim 5, characterized in that the temperature is 10° C. to 70° C.; the stirring time is 30 to 300 min; and the standing time is 3 to 13 days.

### Claim 7 (depends on 5)

The method according to claim 5, characterized in that the solvent is one of or a mixture of more than one of methanol, ethanol, n-propanol, n-butanol, isopropanol, tert-butanol, n-hexanol, ethylene glycol, acetonitrile, acetone, n-hexane or water, wherein progesterone and the cocrystal former are present in a molar ratio of 1:3 to 3:1.

### Claim 8 (depends on 1)

A method for preparing the cocrystal of progesterone according to claim 1, characterized in that the method comprises the following steps: mixing progesterone and the cocrystal former in proportion and placing them in a mortar, adding a solvent dropwise and performing grinding, continuously adding an additional solvent during grinding, and after grinding for 10 to 300 min at a temperature of 10° C. to 50° C., performing drying in a vacuum drying cabinet at 40° C. to 80° C. to obtain a cocrystal of progesterone.

### Claim 9 (depends on 8)

The method according to claim 8, characterized in that the temperature during grinding is 15° C. to 45° C.; the grinding time is 30 to 260 min; and the temperature in the vacuum drying cabinet is 45° C. to 75° C.

### Claim 10 (depends on 8)

The method according to claim 8, characterized in that the solvent is one of or a mixture of more than one of methanol, ethanol, n-propanol, n-butanol, isopropanol, tert-butanol, n-hexanol, ethylene glycol, acetonitrile, acetone, n-hexane or water, wherein progesterone and the cocrystal former are present in a molar ratio of 1:3 to 3:1, preferably 1:2 to 2:1.

### Claim 11 (depends on 1)

A method of using a cocrystal of progesterone for increasing endometrium thickness, improving progesterone's solubility or increasing progesterone's permeation rate comprising administering an effective amount of the cocrystal of progesterone of claim 1 to a patient in need of such cocrystal of progesterone.
